StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin (BMRN) PT Cut to $100 at Baird; Sees Drisapersen Approval 'Near-Zero'
November 23, 2015 7:16 AM
Baird analyst Brian Skorney reiterated a Neutral rating and lowered his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
FDA
Next Articles
FDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - Baird
November 23, 2015 6:55 AM
BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCT
November 20, 2015 12:33 PM
Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners
November 20, 2015 10:21 AM
BioMarin (BMRN) Has Good Risk/Reward Despite Cautious FDA Briefing Documents for Drisapersen, Says RBC
November 20, 2015 10:12 AM
BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)
November 20, 2015 9:50 AM
BioMarin Pharma (BMRN) Announces Consistent Drisapersen Efficacy Evidence Demonstrated Across Three Studies
November 20, 2015 8:12 AM
BioMarin Pharma (BMRN) Affirms Posting of Drisapersen NDA Briefing Docs
November 20, 2015 8:11 AM
BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies
November 20, 2015 8:11 AM
